Scalper1 News
Amgen (AMGN) stock was up 2.5% in afternoon trading on the stock market today after the company presented five studies on its new cholesterol drug over the weekend. Results eased safety concerns raised earlier in the month. Competitors Regeneron (REGN), Sanofi (SNY), Pfizer (PFE) and Bristol-Myers Squibb (BMY) also presented data, but their shares were up a fraction or flat Monday afternoon. At the American College of Cardiology meeting, Amgen Scalper1 News
Scalper1 News